PACB Valuation

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

PACB Relative Valuation

PACB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PACB is overvalued; if below, it's undervalued.

Historical Valuation

Pacific Biosciences of California Inc (PACB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.08 is considered Undervalued compared with the five-year average of 16.12. The fair price of Pacific Biosciences of California Inc (PACB) is between 1.37 to 13.75 according to relative valuation methord. Compared to the current price of 1.13 USD , Pacific Biosciences of California Inc is Undervalued By 17.32%.

Relative Value

Fair Zone

1.37-13.75

Current Price：1.13

17.32%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.66

P/B

Median3y

2.32

Median5y

7.63

-63.73

FCF Yield

Median3y

-26.18

Median5y

-16.05

Competitors Valuation Multiple

The average P/S ratio for PACB's competitors is 4.36, providing a benchmark for relative valuation. Pacific Biosciences of California Inc Corp (PACB) exhibits a P/S ratio of 2.08, which is -52.29% above the industry average. Given its robust revenue growth of -32.79%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PACB.O

Pacific Biosciences of California Inc

2.08

Average P/S: 4.36

-32.79%